Market Overview

UPDATE: BMO Capital Markets Upgrades Tornier to Outperform Ahead of Q3 Earnings

Related TRNX
Benzinga's Top Upgrades, Downgrades For April 11, 2017
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed

BMO Capital Markets raised its rating on Tornier (NASDAQ: TRNX) from Market Perform to Outperform with a reiterated $23 price target.

BMO Capital Markets noted, "As we prepare for the 3Q12 earnings, and look in to 2013, we are upgrading shares of TRNX to OUTPERFORM from MARKET PERFORM, given lowered expectations, a stock that has not recovered after its 2Q12 miss (down 12.9% versus a 6.1% rise in the S&P 1500 HC E&S index since August 7, 2012), and favorable extremities market growth dynamics."

Tornier closed at $10.05 on Monday.

Latest Ratings for TRNX

May 2015Northland SecuritiesInitiates Coverage onMarket Perform
Nov 2014BarclaysMaintainsOverweight
Nov 2014PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for TRNX
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (TRNX)

View Comments and Join the Discussion!

Partner Center